一种花生四烯酸脂质纳米递药系统在制备组合物中的应用
By using the arachidonic acid lipid nanoparticle drug delivery system, the problems of targeting, lysosomal escape, and ferroptosis activation in LNP-delivered siRNA were solved, achieving specific killing of cancer cells and improved stability, thus enhancing therapeutic efficacy and safety.
CN121197093BActive Publication Date: 2026-07-17CENT SOUTH UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CENT SOUTH UNIV
- Filing Date
- 2025-10-22
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing lipid nanoparticles (LNPs) suffer from insufficient targeting, low lysosomal escape efficiency, failure of ferroptosis activation, and safety and stability issues when delivering siRNA, leading to poor therapeutic effects and safety risks.
Method used
The arachidonic acid lipid nanodelivery system is designed by combining ionizable lipids, arachidonic acid, conjugated lipids that inhibit particle aggregation, and the metal ion Fe3+ to improve targeting and lysosomal escape rate and activate ferroptosis mechanism.
Benefits of technology
It achieves specific killing of cancer cells, improves the precision and safety of treatment, and enhances the stability and therapeutic effect of nanoparticles.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN121197093B_ABST
Abstract
本发明公开了一种花生四烯酸脂质纳米递药系统在制备组合物中的应用，涉及生物技术领域，所述脂质纳米递药系统包括以下组分：（1）可电离脂质；（2）花生四烯酸；（3）非阳离子脂质或可电离脂质的抑制颗粒聚集的缀合的脂质；（4）除（3）以外的非阳离子脂质或非可电离脂质；（5）金属离子Fe3+；（6）核酸药物；所述脂质纳米递药系统由至少包括上述（1）至（6）组分自组装形成，所述组合物用于药物的递送。本发明提供了一种新的脂质纳米递药系统及其在制备组合物中的应用，针对铁死亡机制，通过脂质替换及同时使用核核酸药物和金属离子Fe3+，特异性杀伤癌细胞，提升治疗精准度，能增加组合物稳定性以及溶酶体逃逸率。
Need to check novelty before this filing date? Find Prior Art